| __timestamp | Dynavax Technologies Corporation | Verona Pharma plc |
|---|---|---|
| Wednesday, January 1, 2014 | 17763000 | 1802274 |
| Thursday, January 1, 2015 | 22180000 | 2512761 |
| Friday, January 1, 2016 | 37257000 | 2894488 |
| Sunday, January 1, 2017 | 27367000 | 8096274 |
| Monday, January 1, 2018 | 64770000 | 7985229 |
| Tuesday, January 1, 2019 | 74986000 | 8994597 |
| Wednesday, January 1, 2020 | 79256000 | 29772000 |
| Friday, January 1, 2021 | 100156000 | 33907000 |
| Saturday, January 1, 2022 | 131408000 | 26579000 |
| Sunday, January 1, 2023 | 152946000 | 49868547 |
Cracking the code
In the competitive world of biotechnology, managing operational costs is crucial for success. This chart compares the Selling, General, and Administrative (SG&A) expenses of Verona Pharma plc and Dynavax Technologies Corporation from 2014 to 2023. Over this period, Dynavax has consistently outpaced Verona in SG&A spending, with a notable increase of approximately 760% from 2014 to 2023. In contrast, Verona's expenses grew by around 2,670% during the same period, reflecting its strategic investments in growth and development.
By 2023, Dynavax's SG&A expenses reached their peak, accounting for nearly 76% more than Verona's. This trend highlights the differing financial strategies of these two companies, with Dynavax focusing on maintaining a steady growth trajectory, while Verona appears to be ramping up its operational capabilities. Understanding these trends provides valuable insights into the financial health and strategic priorities of these biotech firms.
Breaking Down SG&A Expenses: Merck & Co., Inc. vs Verona Pharma plc
Teva Pharmaceutical Industries Limited and Verona Pharma plc: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Verona Pharma plc
SG&A Efficiency Analysis: Comparing Catalent, Inc. and Verona Pharma plc
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Cost Management Insights: SG&A Expenses for Blueprint Medicines Corporation and Dynavax Technologies Corporation
Madrigal Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Verona Pharma plc vs Ultragenyx Pharmaceutical Inc.
Operational Costs Compared: SG&A Analysis of Verona Pharma plc and Protagonist Therapeutics, Inc.
Verona Pharma plc vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Vericel Corporation vs Dynavax Technologies Corporation